ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
GMP ActiveMax ® Human T Cell Activation/Expansion CD3/CD28 Beads are uniform 5.5 μm magnetic beads coated with an optimized mixture of GMP-grade mouse monoclonal antibodies targeting CD3 and CD28, ...
In this JCO Article Insights episode, Dr. Ece Cal interviews Dr. Martin Wermke, author of the JCO article, "Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager ...
Abpro Holdings, Inc. and Celltrion have announced a strategic partnership for the global development of ABP-102/CT-P72, a bispecific T-cell engager designed to target HER2-positive cancers, which ...
Astellas Pharma Inc. and Vir Biotechnology Inc. have signed a global co-development pact to advance VIR-5500, Vir’s PRO-XTEN dual-masked CD3 T-cell engager targeting prostate-specific membrane antigen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results